This webinar, hosted by Force Family Office, features Gain Therapeutics, a biotech company developing treatments for Parkinson’s disease and other neurodegenerative diseases. The speakers are Steve Saltzstein, the CEO and founder of Force Family Office; John Vandermosten, an analyst at Zacks Small Cap Research; and Matthias Alder, the CEO of Gain Therapeutics. Interested parties may view the video on Gain’s YouTube channel:
Here are the key takeaways from the webinar:
1 – Gain Therapeutics’ lead program, GT-02287, is focused on GBA1 Parkinson’s disease (PD), a genetic form of Parkinson’s caused by a mutation in the GBA1 gene. This program has the potential to be a breakthrough therapy that could slow or even stop the progression of the disease.
2 – Gain Therapeutics uses a computational platform and a physics-based approach to identify drug targets. This platform uses AI to identify novel allosteric binding sites and is one of few computational platforms that has generated a clinical-stage program.
3 – Gain Therapeutics recently published a paper in PLOS ONE on GM1 gangliosidosis, another lysosomal storage disorder. This paper showed that Gain Therapeutics’ platform can be used to restore enzyme function in patients with GM1 gangliosidosis, a common theme with Gain’s lead program. This acts as further evidence of the platform’s ability to find allosteric binding sites on misfolded proteins.
4- Parkinson’s is a large market opportunity in which no disease-modifying therapies exist today.
5 – The M&A landscape for biotech companies is currently very strong. There have been a number of high-profile transactions in recent months, and the overall value of M&A deals in this space has increased year-over-year.
6 – Gain Therapeutics is well-positioned to take advantage of the current M&A environment. The company has a promising clinical-stage program, a strong platform, and a relatively low valuation.
Overall, this webinar provides a comprehensive overview of Gain Therapeutics and its potential for the future. The company’s platform and lead program are both promising, and the current M&A environment could be favorable for Gain Therapeutics.